American family physician|2025|Ebell M
PMID: 40238986
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
The α-ketoacid-hydroxylamine (KAHA) ligation enables the chemoselective coupling of unprotected peptide segments. The most commonly used hydroxylamine building block, ()-5-oxaproline, yields homoserine residues at ligation sites, limiting application…
AIM: This study aimed to clarify the impact of tirzepatide as a treatment for Type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: This single-arm, prospective, observational pilo…
The synthesis of tirzepatide relies heavily on solid phase peptide synthesis (SPPS), a process that is both costly and time-consuming. In this paper, a novel soluble liquid-phase assisted (LPPS) strategy for the efficient synthesis of tirzepatide is…
BACKGROUND: Tirzepatide is commonly used to manage obesity and type 2 diabetes mellitus. Serious neurological symptoms due to tirzepatide were rarely reported. Understanding and managing the adverse events followed by medications have an important ro…
AIMS: This meta-analysis evaluates the rates of pancreatitis/pancreatic cancer among glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in randomised controlled trials (RCTs). METHODS: Following the Preferred Reporting Items for Systematic Reviews…
The SUMMIT trialshowed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with HF with preserved ejection fracti…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastr…
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown unprecedented efficacy in weight loss and improving metabolic parameters in clinical trials. However, the durability of these benefits after treatment cessation remains poorly understood. This…
BACKGROUND: Obstructive sleep apnea (OSA) is a common disorder with major cardiometabolic and neurocognitive sequelae. It affects up to 1 billion people globally and is frequently attributable to excess weight [1]. Tirzepatide is a once-weekly, dual…
BACKGROUND: Incretin mimetics, especially dual/triple agonists, are effective for type 2 diabetes and obesity, though mechanisms remain unclear. This study applied PET using [Ga]Ga-DO3A-Exendin-4 and [Ga]S02-GIP-T4 to assess GLP-1R and GIPR occupancy…